CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) targeting programmed death protein‐1 (PD‐1) or programmed death ligand‐1 (PD‐L1), have brought great changes to the treatment of NSCLC in the past 10 years.